A Phase I study of TSU-68 in patient with non-small cell lung cancer
Phase 1
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-jRCT2080221286
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
1)Patients must be 20 years or more and 74 years or less with Performance Status of 0 to 1.
2)Life expectancy is 12 weeks or more.
3)Adequate oral intake.
4)Patients must have histologically confirmed stage IIIb/IV or recurrent NSCLC.
Exclusion Criteria
1)Patients have colon disorder that is active inflammation.
2)Concurrent of other malignancy.
3)Patients who have been previously treated with investigational products within the past 4 weeks.
4)The subject has hypersensitivity reaction related to CBDCA, PTX or premedication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method